comparemela.com

Latest Breaking News On - Collaboration pharmaceuticals - Page 2 : comparemela.com

Latest Articles

Latest Articles
freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.

AI Creates 40,000 Potential Chemical Weapon Compounds in Six Hours

An AI Machine learning model has created over 40,000 virtual molecules that could be used for chemical weapons in under six hours. 17.03.2022, Sputnik International

AI drug algorithms can be flipped to generate bioweapons

AI drug algorithms can be flipped to generate bioweapons
theregister.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theregister.com Daily Mail and Mail on Sunday newspapers.

Deliberately Optimizing for Harm

Deliberately Optimizing for Harm
science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.

Marburg Virus Disease Pipeline Offers Promising New Options for Treatment

Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.  BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus. Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal an

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.